At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADPT Adaptive Biotechnologies Corp
Post-Mkt 09-23 18:03:03 EDT
27.89
-0.17
-0.61%
盘后28.43
+0.54+1.94%
16:57 EDT
High28.35Low27.60Vol1.08M
Open27.74D1 Closing28.06Amplitude2.67%
Mkt Cap4.46BTradable Cap3.49BTotal Shares159.76M
T/O30.07MT/O Rate0.86%Tradable Shares125.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Adaptive Biotechnologies Price Target Raised to $34.00/Share from $25.00 by BTIG
Dow Jones  ·  09-22 18:19
Adaptive Biotechnologies Price Target Raised to $34.00/Share from $25.00 by BTIG
Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 1,195 Shares for $32,265
Reuters  ·  09-18
Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 1,195 Shares for $32,265
Adaptive Biotechnologies reports update to NCCN guidelines for Multiple Myeloma
TIPRANKS  ·  09-17
Adaptive Biotechnologies reports update to NCCN guidelines for Multiple Myeloma
Adaptive Biotechnologies Announces Update to Nccn Guidelines® for Multiple Myeloma, Strengthening Mrd Testing Recommendations and Specifically Referencing Clonoseq®
THOMSON REUTERS  ·  09-17
Adaptive Biotechnologies Announces Update to Nccn Guidelines® for Multiple Myeloma, Strengthening Mrd Testing Recommendations and Specifically Referencing Clonoseq®
Alert Incorrectly Tagged to Adaptive Biotechnologies Withdrawn
Reuters  ·  09-17
Alert Incorrectly Tagged to Adaptive Biotechnologies Withdrawn
Adaptive Raises $30 Million Series B Led by Tidemark to Bring Agentic Accounting to Construction
THOMSON REUTERS  ·  09-17
Adaptive Raises $30 Million Series B Led by Tidemark to Bring Agentic Accounting to Construction
Adaptive Biotechnologies Director Katey Einterz Owen Sells 9,615 Shares for $249,990
Reuters  ·  08-29
Adaptive Biotechnologies Director Katey Einterz Owen Sells 9,615 Shares for $249,990
Adaptive Biotechnologies (ADPT), Why Is It Getting Fresh Attention Now?
Simply Wall St.  ·  08-28
Adaptive Biotechnologies (ADPT), Why Is It Getting Fresh Attention Now?
Adaptive Biotechnologies Director Peter M. Neupert Disposes of 124,690 Common Shares for $3.14 Million
Reuters  ·  08-20
Adaptive Biotechnologies Director Peter M. Neupert Disposes of 124,690 Common Shares for $3.14 Million
Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales
Simply Wall St.  ·  08-13
Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales
Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 3,000 Shares for $75,000
Reuters  ·  08-13
Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 3,000 Shares for $75,000
Adaptive Biotechnologies is Maintained at Overweight by Piper Sandler
Dow Jones  ·  08-04
Adaptive Biotechnologies is Maintained at Overweight by Piper Sandler
U.S. Research Roundup-Cloudflare, Replimune, Walmart
Reuters  ·  08-04
U.S. Research Roundup-Cloudflare, Replimune, Walmart
Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176
Reuters  ·  08-04
Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 1,299 Common Shares for $31,176
Veracyte Q2 Revenue Rises on Decipher and Afirma Test Sales
Reuters  ·  07-31
Veracyte Q2 Revenue Rises on Decipher and Afirma Test Sales
Fulgent Genetics Q2 Revenue Rises 20% Sequentially, Sees Billing System Transition Delay
Reuters  ·  07-31
Fulgent Genetics Q2 Revenue Rises 20% Sequentially, Sees Billing System Transition Delay
CareDx Q2 Revenue Beats Estimates; Outlook Lifted
Reuters  ·  07-31
CareDx Q2 Revenue Beats Estimates; Outlook Lifted
Adaptive Biotechnologies is Maintained at Buy by Guggenheim
Dow Jones  ·  07-30
Adaptive Biotechnologies is Maintained at Buy by Guggenheim
Adaptive Biotechnologies price target raised to $25 from $24 at BTIG
TIPRANKS  ·  07-30
Adaptive Biotechnologies price target raised to $25 from $24 at BTIG
Adaptive Biotechnologies Corp : Morgan Stanley Raises Target Price to $22 from $20
THOMSON REUTERS  ·  07-30
Adaptive Biotechnologies Corp : Morgan Stanley Raises Target Price to $22 from $20

Introduction

Company Name.
Adaptive Biotechnologies Corp
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Issue price:
--